Cationic liposomes as carriers for gene delivery Physico-chemical characterization and mechanism of cell transfection

Purpose: Although cationic liposomes are widely used non-viral gene vectors, the structure–activity relationships governing their transfection efficiency remain poorly understood, and optimization is still largely trial-and-error. A systematic in vitro study was needed to correlate lipoplex physicochemical properties and intracellular trafficking with transfection efficiency and toxicity.

Hypothesis: The authors did not state a formal hypothesis; the inferred working claim is that transfection efficiency depends on liposome/pDNA weight ratio, lipoplex morphology and size, and intracellular pDNA delivery to the nucleus. Specifically, filamentous lipoplexes may release pDNA more easily after endocytosis and yield higher transfection than compact globular complexes, and Lipofectamine 2000 may transport pDNA to the nucleus more efficiently than DOTAP.

Aims: Examine correlations among lipoplex morphology, size, cell density, DNA amount, liposome/pDNA weight ratio, complex formation time, transfection time, serum, and cell line with transfection efficiency and toxicity. - Physicochemically characterize cationic liposomes and lipoplexes using AFM, DLS, and gel electrophoresis. - Compare Lipofectamine 2000 and DOTAP as model cationic liposome systems. - Visualize intracellular trafficking of fluorescently labeled pDNA and liposomes to study the mechanism of cationic lipid-mediated gene delivery.

Delivery system: Platform: Cationic liposomes. - Lipofectamine 2000: proprietary mixture containing DOSPA, DOTMA, and DOPE; polyamine head group. - DOTAP: DOTAP/DOPE at 1:1 ratio. - Payload: pGL3-control plasmid encoding firefly luciferase; pGFP-N2 plasmid encoding green fluorescent protein; Rhodamine-labeled pGL3-control for trafficking. - Labeling: Liposomes labeled with 5 mol% NBD-PE for confocal imaging. - Complexation: Liposome/pDNA weight ratios from 0.5 to 8; typical transfection ratios 2, 3, 4, 5, and 7. - Targeting ligand: None. - Model: In vitro only.

Approach: Cell lines: HeLa, Hep-2, SMMC-7721, HT-29, SW480, MCF-7, and B16 cells. - Transfection format: 96-well plates; 0.5–2 × 10⁴ cells/well; cells at ~80% confluence; 0.3 or 0.5 µg pDNA per well; 4–6 h incubation with lipoplexes, then complete medium for 24–48 h. - Key variables: Cell density, pDNA amount, liposome/pDNA weight ratio, complex formation time, transfection time, serum presence, and cell type. - Controls/comparisons: Naked pDNA, Lipofectamine 2000 vs DOTAP, with/without serum. - Replication: DLS measurements repeated three times; GFP counting performed in three repeats; some transfection data shown as averages.

Key methods: Atomic force microscopy (AFM) for liposome and lipoplex morphology and size. - Dynamic light scattering (DLS) for particle size and zeta potential. - Agarose gel electrophoresis for pDNA binding/retardation. - Luciferase assay for transfection efficiency (RLU/mg protein). - GFP fluorescence microscopy for transfection efficiency. - MTT assay for cytotoxicity. - Confocal laser scanning microscopy for intracellular trafficking of NBD-labeled liposomes and Rhodamine-labeled pDNA.

Key results: Morphology: Lipofectamine 2000/pDNA lipoplexes formed filaments and granules at weight ratio 3, with diameters from 466 to 1377 nm. DOTAP/pDNA formed more compact globular structures at ratios 6 and 8, with diameters from 100 to 247 nm. - Size and charge: Lipofectamine 2000/pDNA lipoplex size increased from 150 to 475 nm as weight ratio increased. Zeta potentials were -22.4, -16.3, and -12.4 mV at weight ratios 1, 3, and 5, respectively. pDNA was completely retained at weight ratio 8 for Lipofectamine 2000 but not for DOTAP. - Transfection efficiency: Maximum expression reached ~500,000 RLU/mg luciferase in HeLa cells. Optimal Lipofectamine 2000 ratio was 3–4 with 0.3 µg pDNA, or 2–3 with 0.5 µg pDNA; DOTAP optimum was ratio 6. Filamentous lipoplexes gave higher transfection than globular ones. Optimal cell density was 1–2 × 10⁴ cells/well; complex formation ~30 min; transfection time 4 h. Serum did not significantly affect Lipofectamine 2000. HeLa and Hep-2 showed higher expression; HT29 and SMMC-7721 were low. Lipofectamine 2000 was significantly higher than DOTAP in HeLa and MCF-7. - Cytotoxicity: Lipofectamine 2000 showed <10% toxicity; DOTAP showed <20%; toxicity was cell-specific, with B16 and Hep-2 more affected. - Intracellular trafficking: At 2 h, lipoplexes bound and internalized. Lipofectamine 2000 delivered Rhodamine-labeled pDNA to nuclei at higher frequency than DOTAP. Green liposome fluorescence was not observed in nuclei, suggesting the lipid detached from pDNA and remained in the cytoplasm/endosomes.

Interpretation: The authors conclude that lipid structure, liposome/pDNA weight ratio, and lipoplex morphology are among the most important determinants of transfection efficiency, with pDNA release from the complex being crucial. They suggest that understanding these parameters can guide rational modification of lipid vectors and improve non-viral therapeutic gene delivery.

Limitations: In vitro study only; no in vivo validation. - Uses commercial liposome formulations rather than newly engineered vectors. - Transfection efficiency and toxicity were highly cell-type dependent. - Mechanistic conclusions rely mainly on confocal imaging. - Serum did not affect Lipofectamine 2000 in vitro, but the authors note that in vitro-efficient carriers often fail in vivo due to serum sensitivity. - Cationic lipid toxicity remains an obstacle for clinical application.